Citigroup’s Keros Therapeutics KROS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $459K | Sell |
34,379
-37,378
| -52% | -$499K | ﹤0.01% | 2979 |
|
|
2025
Q1 | $731K | Buy |
71,757
+17,334
| +32% | +$177K | ﹤0.01% | 2739 |
|
|
2024
Q4 | $862K | Buy |
54,423
+31,042
| +133% | +$491K | ﹤0.01% | 2685 |
|
|
2024
Q3 | $1.36M | Buy |
23,381
+10,798
| +86% | +$627K | ﹤0.01% | 2328 |
|
|
2024
Q2 | $575K | Sell |
12,583
-104,873
| -89% | -$4.79M | ﹤0.01% | 2609 |
|
|
2024
Q1 | $7.78M | Sell |
117,456
-51,935
| -31% | -$3.44M | 0.01% | 1021 |
|
|
2023
Q4 | $6.73M | Buy |
169,391
+71,282
| +73% | +$2.83M | ﹤0.01% | 993 |
|
|
2023
Q3 | $3.13M | Sell |
98,109
-54,738
| -36% | -$1.75M | ﹤0.01% | 1243 |
|
|
2023
Q2 | $6.14M | Sell |
152,847
-173,217
| -53% | -$6.96M | ﹤0.01% | 1003 |
|
|
2023
Q1 | $13.9M | Sell |
326,064
-86,039
| -21% | -$3.67M | 0.01% | 720 |
|
|
2022
Q4 | $19.8M | Sell |
412,103
-64,020
| -13% | -$3.07M | 0.02% | 565 |
|
|
2022
Q3 | $17.9M | Buy |
476,123
+13,753
| +3% | +$517K | 0.01% | 591 |
|
|
2022
Q2 | $12.8M | Buy |
462,370
+454,498
| +5,774% | +$12.6M | 0.01% | 746 |
|
|
2022
Q1 | $428K | Sell |
7,872
-24,248
| -75% | -$1.32M | ﹤0.01% | 2953 |
|
|
2021
Q4 | $1.88M | Buy |
32,120
+13,518
| +73% | +$791K | ﹤0.01% | 2022 |
|
|
2021
Q3 | $736K | Sell |
18,602
-22,942
| -55% | -$908K | ﹤0.01% | 2627 |
|
|
2021
Q2 | $1.76M | Sell |
41,544
-1,153
| -3% | -$49K | ﹤0.01% | 2179 |
|
|
2021
Q1 | $2.63M | Buy |
42,697
+39,391
| +1,192% | +$2.42M | ﹤0.01% | 1767 |
|
|
2020
Q4 | $233K | Buy |
3,306
+2,971
| +887% | +$209K | ﹤0.01% | 3151 |
|
|
2020
Q3 | $13K | Sell |
335
-608
| -64% | -$23.6K | ﹤0.01% | 4173 |
|
|
2020
Q2 | $35K | Buy |
+943
| New | +$35K | ﹤0.01% | 3928 |
|